ArticleFrontiers in cardiovascular medicine2026
Efficacy and safety of levosimendan in acute heart failure patients with different body mass index: a multicenter, retrospective, observational real-world study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and safety of levosimendan in acute heart failure (AHF) patients with different body mass index (BMI) using real-world data. Methods: This retrospective study enrolled 2,398 AHF patients hospitalized at 14 provincial, municipal, and county-level hospitals in Jiangxi Province from March 1, 2023, to March 1, 2025. After excluding 828 cases due to missing data and 60 cases with BMI < 18.5 kg/m Results: After 7 days of levosimendan treatment, patients showed significant reductions in SBP and DBP compared to pre-treatment levels ( Conclusions: 1. In patients with acute heart failure, levosimendan administration was associated with a decreasing trend in plasma NT-proBNP levels, an improvement in left ventricular ejection fraction, and alleviation of cardiac functional impairment and respiratory symptoms. Favorable safety profiles were generally observed during the treatment period. 2. Body mass index showed a negative correlation with NT-proBNP levels, suggesting that patients with higher BMI tend to have relatively lower baseline NT-proBNP levels. 3. In acute heart failure patients stratified by body mass index, levosimendan treatment exhibited between-group variations in clinical parameter improvements and safety profiles. Overweight and obese subgroups demonstrated a tendency toward more pronounced clinical improvement and fewer reported adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.